We protect your health through science
Investigation
Viral Biology
Publications
Full coding hepatitis E virus genotype 3 genome amplification method.
Muñoz-Chimeno M, Forero JE, Echevarría JM, Muñoz-Bellido JL, Vázquez-López L, Morago L, García-Galera MC, Avellón A. Full coding hepatitis E virus genotype 3 genome amplification method. J Virol Methods. 2016 Apr;230:18-23.
PUBMED DOIComparative sensitivity of commercial tests for hepatitis E genotype 3 virus antibody detection.
• Avellón A, Morago L, García-Galera del Carmen M, Muñoz M, Jose-Manuel Echevarría JM. Comparative sensitivity of commercial tests for hepatitis E genotype 3 virus antibody detection. J Med Virol. 2015 Nov;87(11):1934-9.
PUBMED DOIEpidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain
11: Puig-Asensio M, Padilla B, Garnacho-Montero J, Zaragoza O, Aguado JM, Zaragoza R, Montejo M, Muñoz P, Ruiz-Camps I, Cuenca-Estrella M, Almirante B; CANDIPOP Project; GEIH-GEMICOMED (SEIMC); REIPI. Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain. Clin Microbiol Infect. 2014 Apr;20(4):O245-54.
PUBMED DOIB Pérez de Val, B Romero, MT Tórtola, L Herrera-León, P Pozo, I Mercader, JL Sáez, M Domingo, E Vidal. Poly-resistant Mycobacterium bovis infection in a human and sympatric sheep, Spain, 2017-2018
B Pérez de Val, B Romero, MT Tórtola, L Herrera-León, P Pozo, I Mercader, JL Sáez, M Domingo, E Vidal. Poly-resistant Mycobacterium bovis infection in a human and sympatric sheep, Spain, 2017-2018. Emerg Infect Dis. 2021 Apr;27(4):1241-1243. doi: 10.3201/eid2704.204467. PMID: 33755008.
DOIContent with Investigacion .
-
Isabel de Fuentes Corripio
Jefa de Unidad, Investigador Titular OPIS
-
David Carmena Jiménez
Investigador Doctor distinguido
-
Aly Salimo Omar Muadica
Becario pre-doctoral
-
Marta Hernández de Mingo
Colaborador I+D+I
-
Begoña Bailo Cardoso
Técnico de Laboratorio
-
María Aguilera
Técnico de laboratorio
-
David González Barrio
Investigador contratado
List of staff
Additional Information
The research activity of the Viral Biology group since its beginnings in the 1980s has focused on respiratory viruses, especially on the study of the mechanisms of virus entry into the cell, evolutionary aspects, antigenic properties and vaccine development.
Currently, the group's objectives are focused on the characterisation of the immune response and the development of vaccines against human pneumoviruses: human respiratory syncytial virus (hRSV) and human metapneumovirus (hMPV).
Both viruses are considered to be important respiratory pathogens of high clinical relevance, especially in the paediatric population.
Safe and effective vaccines against these viruses are currently not available. Soluble protein subunits based on the fusion protein (F-protein) of hRSV and hMPV are being developed in the laboratory by protein engineering for use as vaccines against human pneumoviruses.
On the other hand, and thanks to the characterisation of the type of humoral response induced by the F proteins of these viruses, the laboratory is also involved in the isolation of monoclonal antibodies and nanoantibodies for use as treatments against these viruses.
The research activity of the Viral Biology group since its beginnings in the 1980s has focused on respiratory viruses, especially on the study of the mechanisms of virus entry into the cell, evolutionary aspects, antigenic properties and vaccine development.
Currently, the group's objectives are focused on the characterisation of the immune response and the development of vaccines against human pneumoviruses: human respiratory syncytial virus (hRSV) and human metapneumovirus (hMPV).
Both viruses are considered to be important respiratory pathogens of high clinical relevance, especially in the paediatric population.
Safe and effective vaccines against these viruses are currently not available. Soluble protein subunits based on the fusion protein (F-protein) of hRSV and hMPV are being developed in the laboratory by protein engineering for use as vaccines against human pneumoviruses.
On the other hand, and thanks to the characterisation of the type of humoral response induced by the F proteins of these viruses, the laboratory is also involved in the isolation of monoclonal antibodies and nanoantibodies for use as treatments against these viruses.